

## ESTIMATED ANNUALIZED BURDEN HOURS—Continued

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hr)
	Study Salt Supplement Questionnaire .....	75	3	5/60

**Ron A. Otten,**

Director, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention.

[FR Doc. 2013–13038 Filed 5–31–13; 8:45 am]

BILLING CODE 4163–18–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[30Day–13–13BF]

#### Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. chapter 35). To request a copy of these requests, call (404) 639–7570 or send an email to [omb@cdc.gov](mailto:omb@cdc.gov). Send written comments to CDC Desk Officer, Office of Management and Budget, Washington, DC 20503 or by fax to (202) 395–5806. Written comments should be received within 30 days of this notice.

#### Proposed Project

Spectrum of Flavoring Chemical-Related Lung Disease—New—National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention (CDC).

#### Background and Brief Description

This project involves a questionnaire, along with clinical testing, to investigate and characterize the nature of lung disease occurring in popcorn and flavoring workers. Since publication of the 60-day **Federal Register** Notice, the annual burden estimate has been revised. We added the inclusion of job and medication forms to be completed by the participant prior to the testing session. We also included the time needed to review the informed consent. The overall burden hours is now estimated to be 115 hours.

The purpose of this study is to investigate the spectrum of lung disease occurring in flavoring and microwave popcorn workers. A secondary aim is to study the natural history of lung disease. For this study, we plan on interviewing and conducting clinical testing on participants from a previously investigated flavoring plant and microwave popcorn plant.

For this study, we will recruit participants from two study populations: Approximately 112

workers from a flavorings plant for whom we have spirometry data and 132 workers that had abnormal spirometry on any test from a previous NIOSH health hazard evaluation at a microwave popcorn plant. Thirty additional workers from the microwave popcorn plant who had normal spirometry on their last test also will be chosen at random.

NIOSH anticipates that information collection will begin in the 2013 fiscal year for the microwave popcorn workers and for the flavorings workers in fiscal year 2014. Prior to the testing, participants will be mailed a copy of the informed consent to review and asked to complete a job history form and current medication form. This will take no more than 25 minutes (total) to review and complete. On the day of testing, a NIOSH staff member will review the consent form with the participant, which will take about 5 minutes. Participants will then be given a NIOSH-administered questionnaire which will take approximately 20 minutes to complete. All study results will be stored at NIOSH.

Participation in all components of the study is completely voluntary. There are no costs to the respondents other than their time. The total estimated annual burden hours are 115.

## ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hours)
Popcorn workers .....	Informed consent .....	81	1	15/60
	Medication form .....	81	1	5/60
	Job history form .....	81	1	10/60
	Questionnaire .....	81	1	20/60
Flavoring workers .....	Informed consent .....	56	1	15/60
	Medication form .....	56	1	5/60
	Job history form .....	56	1	10/60
	Questionnaire .....	56	1	20/60

**Ron A. Otten,**

*Director, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention.*

[FR Doc. 2013-12978 Filed 5-31-13; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[CDC-2013-0007; NIOSH-233]

#### NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2014: Proposed Additions and Deletions to the NIOSH Hazardous Drug List

**AGENCY:** National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of Draft Document Available for Public Comment.

**SUMMARY:** The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the availability of the following draft document for public comment entitled “NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2014: Proposed Additions and Deletions to the NIOSH Hazardous Drug List.” The document and instructions for submitting comments can be found at <http://www.regulations.gov>.

This guidance document does not have the force and effect of law.

**Public Comment Period:** Comments must be received by August 2, 2013.

**ADDRESSES:** You may submit comments, identified by CDC-2013-0007 and Docket Number NIOSH-233, by either of the two following methods:

- **Federal eRulemaking Portal:** <http://www.regulations.gov>. Follow the instructions for submitting comments.
- **Mail:** NIOSH Docket Office, Robert A. Taft Laboratories, MS-C34, 4676 Columbia Parkway, Cincinnati, Ohio 45226.

Instructions: All information received in response to this notice must include the agency name and the docket number (CDC-2003-0007; NIOSH-233). All relevant comments received will be posted without change to <http://www.regulations.gov>, including any personal information provided. All electronic comments should be

formatted as Microsoft Word. Please make reference to CDC-2013-0007 and Docket Number NIOSH-233.

#### **SUPPLEMENTARY INFORMATION:**

**Background:** The NIOSH Alert: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings was published in September 2004 (<http://www.cdc.gov/niosh/docs/2004-165/>). This Alert contained Appendix A which was a list of drugs that were deemed to be hazardous and may require special handling. This list of hazardous drugs was updated in 2010 and 2012 and covered all new approved drugs and drugs with new warning up to December 2009. (<http://www.cdc.gov/niosh/docs/2010-167/>; <http://www.cdc.gov/niosh/docs/2012-150/>). Between January 2010 and December 2011, 48 new drugs received FDA approval and 276 drugs received special warnings (usually black box warnings) based on reported adverse effects in patients. From this list of 324 drugs, 42 drugs were identified by NIOSH as candidate hazardous drugs. Four of these drugs had safe handling recommendations from the manufacturer and NIOSH is following the recommendations of the manufacturers. Therefore, these four drugs will be listed as hazardous without requiring further review. A panel consisting of peer reviewers and stakeholders was asked to review and comment on the remaining 38 potentially hazardous drugs. In addition, the panel members were asked to comment on the addition of one drug requested by several stakeholders and the removal of one drug from the 2012 Hazardous Drug List. Reviewers were not asked to provide a consensus opinion and NIOSH made the final determination regarding additions and deletions to the 2014 hazardous drug list.

NIOSH reviewed the recommendations of the peer reviewers and stakeholders and determined that 24 drugs in addition to the 4 drugs with manufacturer's warnings, were determined to have one or more characteristics of a hazardous drug and this list of 28 drugs is being published for comment in CDC-2013-0007 and NIOSH Docket Number 233. In addition, 1 drug from the 2012 Hazardous Drug List is being considered for removal. The complete list of these drugs can be found at: <http://www.regulations.gov> as a supporting document.

**FOR FURTHER INFORMATION CONTACT:** Barbara MacKenzie, NIOSH, Robert A. Taft Laboratories, 4676 Columbia Parkway, MS-C26, Cincinnati, Ohio

45226, telephone (513) 533-8132, Email [hazardousdrugs@cdc.gov](mailto:hazardousdrugs@cdc.gov).

Dated: May 24, 2013.

#### **John Howard,**

*Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.*

[FR Doc. 2013-13043 Filed 5-31-13; 8:45 am]

**BILLING CODE 4163-19-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Agency Information Collection Activities; Proposed Collection; Comment Request: Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery, National Institute of Neurological Disorders and Stroke (NINDS)

**SUMMARY:** As part of a Federal Government-wide effort to streamline the process to seek feedback from the public on service delivery, the National Institute of Neurological Disorders (NINDS) has submitted a Generic Information Collection Request (Generic ICR): “Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery” to OMB for approval under the Paperwork Reduction Act (PRA) (44 U.S.C. 3501 et. seq.).

**DATES:** Comments must be submitted within 30 days after publication in the **Federal Register**.

**ADDRESSES:** Written comments may be submitted to the Office of Management and Budget, Office of Information and Regulatory Affairs, Attn: NIH Desk Officer, by Email to [OIRA\\_submission@omb.eop.gov](mailto:OIRA_submission@omb.eop.gov), or by fax to 202-395-6974.

**FOR FURTHER INFORMATION CONTACT:** To request additional information, please contact: Paul Scott, Ph.D., Director, Office of Science Policy and Planning, NINDS, 31/8A03 Center Drive, Bethesda, MD 20892-2178, or Email your request, including your address to [scott@ninds.nih.gov](mailto:scott@ninds.nih.gov).

#### **SUPPLEMENTARY INFORMATION:**

**Title:** Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery.

**Abstract:** The information collection activity will garner qualitative customer and stakeholder feedback in an efficient, timely manner, in accordance with the Administration's commitment to improving service delivery. By qualitative feedback we mean information that provides useful insights on perceptions and opinions,